Daily Sepsis Research Analysis
Analyzed 18 papers and selected 3 impactful papers.
Summary
Three impactful sepsis studies span mechanistic immunology and bedside antimicrobial optimization. Two preclinical papers reveal novel immunometabolic and innate immune checkpoints (α-ketoglutarate/TET2/AIM2 PANoptosis and FSTL1–STING autophagy axis) driving inflammatory cell death and immunosuppression, while a clinical cohort shows rapid phenotypic susceptibility testing enabling earlier active therapy and lower mortality in Gram-negative bloodstream infections.
Research Themes
- Immunometabolism and epigenetic control of inflammatory cell death in sepsis
- STING-autophagy regulation and dendritic cell pyroptosis driving immunosuppression
- Rapid phenotypic antimicrobial susceptibility testing to optimize early therapy in MDR settings
Selected Articles
1. The metabolite α-ketoglutarate induces AIM2-dependent PANoptosis through demethylase TET2.
This mechanistic study identifies α-ketoglutarate as an immunometabolic checkpoint that enhances TET2 activity to epigenetically upregulate AIM2, assembling the PANoptosome and driving inflammatory macrophage death during sepsis. Pharmacologic or genetic lowering of α-KG, or blocking TET2/AIM2 signaling, attenuated inflammation and tissue injury.
Impact: Reveals a previously unrecognized α-KG/TET2/AIM2 axis linking metabolism to inflammatory cell death in sepsis, highlighting tractable therapeutic targets. Provides multi-system evidence bridging clinical samples and experimental models.
Clinical Implications: Caution with α-KG-raising interventions; targeting TET2 activity, AIM2 expression, or α-KG production (e.g., IDH1 inhibition) could modulate hyperinflammation. Identifies candidate biomarkers for stratifying inflammatory death phenotypes.
Key Findings
- DM-α-KG exacerbated LPS-induced tissue injury and inflammatory cell death, while IDH1 inhibition or genetic ablation reduced α-KG and conferred protection.
- α-KG enhanced TET2 dioxygenase activity, decreased methylation at the AIM2 promoter, increased AIM2 expression, and triggered PANoptosome assembly.
- Inflammation was attenuated by TET inhibition (DMOG) or AIM2 deletion, validating the α-KG/TET2/AIM2 axis in sepsis pathophysiology.
Methodological Strengths
- Integrated clinical samples with in vivo and in vitro experimental models
- Convergent pharmacologic (DM-α-KG, IDH-305, DMOG) and genetic perturbations to validate causality
Limitations
- Translational gap from animal/cellular models to human therapeutic efficacy
- Potential off-target effects of metabolic and epigenetic inhibitors not fully excluded
Future Directions: Validate α-KG/TET2/AIM2 signatures in prospective human sepsis cohorts; develop selective modulators and test in sepsis-relevant preclinical models; assess safety of targeting immunometabolic pathways.
While α-ketoglutarate (α-KG) has traditionally been viewed as an anti-inflammatory metabolite, we uncover its paradoxical role in driving pathological inflammation during sepsis. This study reveals that α-KG, a tricarboxylic acid cycle (TCA) intermediate elevated in septic patients, drives inflammatory macrophage death through absent in melanoma 2 (AIM2) -PANoptosome activation. Using both clinical samples and experimental models, we demonstrate that the cell-permeable derivative dimethyl-α-ketoglutarate (DM-α-KG) exacerbates lipopolysaccharide (LPS)-induced tissue injury and cell death, whereas isocitrate dehydrogenase (IDH1) inhibition (IDH-305) or genetic ablation reduces α-KG levels and confers protection. Mechanistically, α-KG enhances the dioxygenase activity of Ten-eleven translocation 2 (TET2), promoting its binding to the AIM2 promoter, reducing methylation, and increasing AIM2 expression, thereby triggering PANoptosome assembly. The pathophysiological relevance of this axis was confirmed by attenuated inflammation following either TET inhibition (dimethyloxallyl glycine, DMOG) or AIM2 deletion. These findings establish α-KG as a critical immunometabolic checkpoint in sepsis that licenses inflammatory cell death via TET2-mediated epigenetic control of AIM2. Our work not only elucidates a novel α-KG/TET2/AIM2 signaling axis in sepsis pathogenesis but also highlights the therapeutic potential of targeting this pathway to modulate immune responses.
2. Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study.
In a high-MDR ICU cohort with Gram-negative bacteremia, rapid phenotypic AST enabled earlier active therapy and was associated with markedly lower 30-day mortality and clinical failure compared to conventional AST. Time-to-event analyses supported RAST-guided management and early active therapy as independent predictors of survival.
Impact: Demonstrates real-world mortality benefit associated with implementing rapid phenotypic susceptibility testing, directly informing antimicrobial stewardship and early source therapy decisions in sepsis care.
Clinical Implications: Adopting RAST in ICUs with high MDR prevalence can accelerate appropriate therapy, reduce clinical failure, and potentially lower mortality in Gram-negative sepsis. Integration with stewardship protocols and rapid reporting workflows is warranted.
Key Findings
- 30-day mortality was lower with RAST vs conventional AST (10.8% vs 31.3%, P=0.015).
- Early active antimicrobial therapy was more frequent with RAST (86.5% vs 45.8%, P<0.001).
- Clinical failure occurred in 0% with RAST vs 20.8% with AST (P=0.003).
- RAST-guided management (HR 0.16, 95% CI 0.04–0.62) and early active therapy (HR 0.51, 95% CI 0.19–0.94) independently predicted survival.
Methodological Strengths
- Real-world ICU cohort in a high-MDR context
- Multivariable Cox regression confirming independent associations
Limitations
- Retrospective single-center design with small RAST sample size
- Potential residual confounding and selection bias; limited generalizability
Future Directions: Prospective, multicenter trials to confirm mortality benefit, define turnaround time thresholds, and assess cost-effectiveness and microbiologic subgroup effects.
OBJECTIVES: This study assessed the real-world clinical impact of rapid antimicrobial susceptibility testing (RAST) compared with conventional susceptibility testing (AST) in critically ill patients with Gram-negative bloodstream infections (GNB BSIs), focusing on early optimization of therapy and clinical outcomes in a high multidrug-resistant (MDR) setting. METHODS: We conducted a retrospective, observational study including adult patients with GNB BSIs who were stratified according to the susceptibility testing strategy used (RAST or conventional AST). The primary outcome was 30-day all-cause mortality. Secondary outcomes included administration of early active antimicrobial therapy, clinical failure and length of both intensive care unit (ICU) and hospital stay. RESULTS: A total of 133 patients were included (RAST: 37; AST: 96). Thirty-day mortality was observed in 4/37 patients (10.8%) in the RAST group and in 30/96 (31.3%) in the AST group (P = 0.015). Early active therapy was administered to 32/37 (86.5%) RAST patients versus 44/96 (45.8%) in the AST group (P < 0.001). Clinical failure occurred in 0/37 RAST patients versus 20/96 (20.8%) AST patients (P = 0.003). Mean ICU stay was 30.3 ± 22.9 days (RAST) versus 36.9 ± 25.6 days (AST), P = 0.17. In Cox regression analysis, RAST-guided management (HR = 0.16, 95% CI 0.04-0.62) and early active therapy (HR = 0.51, 95% CI 0.19-0.94) were independently associated with survival. CONCLUSIONS: RAST may represent a valuable tool to optimize antimicrobial therapy in critically ill patients with GNB BSIs, particularly considering the increasing prevalence of MDR pathogens.
3. FSTL1 promotes dendritic cell pyroptosis and immunosuppression in sepsis by inhibiting STING autophagy.
FSTL1 blocks autophagic degradation of STING, leading to its accumulation, dendritic cell pyroptosis, impaired T-cell priming, and in vivo immunosuppression in sepsis. Pharmacologic STING inhibition reversed FSTL1-driven pyroptosis, organ injury, and mortality in murine models.
Impact: Defines a mechanistic FSTL1–STING-autophagy axis linking elevated FSTL1 to DC death and septic immunosuppression, nominating STING modulation and FSTL1 as therapeutic/biomarker targets.
Clinical Implications: Targeting STING autophagy or FSTL1 signaling may preserve DC function and mitigate late immunosuppression in sepsis; FSTL1 levels could aid risk stratification.
Key Findings
- FSTL1 levels were elevated and correlated with dendritic cell pyroptosis in vitro and in septic mice.
- FSTL1 inhibited autophagic degradation of STING, causing STING accumulation/activation and impaired T-cell priming.
- STING inhibition (C-176) attenuated FSTL1-induced pyroptosis, restored DC-mediated T-cell activation, and reversed increased organ injury and mortality in murine sepsis.
Methodological Strengths
- Use of complementary in vitro and in vivo sepsis models with pathway-specific agonists/inhibitors
- Orthogonal assays (Western blot, flow cytometry, immunofluorescence, co-immunoprecipitation) to define mechanism
Limitations
- Preclinical models limit direct clinical generalizability
- Pharmacologic tools (e.g., C-176, 3-MA) may have off-target effects
Future Directions: Quantify FSTL1 and STING-autophagy biomarkers in human sepsis cohorts; develop selective autophagy/ STING modulators; test DC-preserving strategies in translational models.
BACKGROUND: Sepsis-induced immunosuppression, characterized by dendritic cell (DC) depletion, correlates with poor outcomes. The glycoprotein FSTL1 is elevated in sepsis, but its contribution to DC pyroptosis and subsequent immune dysfunction remains unknown. METHODS: We utilized in vitro models with splenic DCs and mouse dendritic cell line DC2.4, alongside a murine cecal ligation and puncture (cecal ligation and puncture) sepsis model. The roles of STING and autophagy were probed using specific modulators (STING agonist DMXAA; STING specific inhibitor C-176; autophagy inhibitor 3-methyladenine). Pyroptosis was assessed by quantifying cleaved CASP1 and GSDMD-N via Western blotting and flow cytometry. STING pathway activation and autophagic flux were evaluated by detecting protein phosphorylation (p-STING, p-TBK1) and key markers (LC3B, P62) through Western blotting, immunofluorescence, and co-immunoprecipitation. DC-mediated T-cell responses were determined by proliferation assays and cytokine secretion analysis. RESULTS: FSTL1 was found elevated and correlated withDC pyroptosis in vitro and in septic mice. Mechanistically, FSTL1 inhibited the autophagic degradation of STING, leading to its accumulation and subsequent activation. Consequently, this impaired T-cell priming capacity and resulted in immunosuppression in vivo. Inhibition of STING attenuated FSTL1-induced pyroptosis, restored DC-mediated T-cell activation, and ameliorated immunosuppression. In murine septic models, FSTL1 exacerbated multiple organ injury and increased mortality, effects that were reversed by STING inhibition. CONCLUSION: Our findings demonstrate that FSTL1 correlates with impaired STING autophagic degradation and DC pyroptosis, suggesting a potential pathway contributing to septic immune dysfunction.